Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560220 | 0.81 | SLC6A2 (0.46) | SIGMAR1MAOASLC6A2TAAR1SLC6A4 | |
| SCHEMBL21194619 | 0.77 | HTR6 (0.53) | IDO1HTR2APDPK1ADRA1ARET | |
| SCHEMBL11884022 | 0.77 | ADRA1A (0.44) | IDO1HTR2APDPK1ADRA1ASIGMAR1 | |
| SCHEMBL29462285 | 0.77 | HTR6 (0.53) | IDO1HTR2APDPK1ADRA1ARET | |
| SCHEMBL9570548 | 0.73 | ADRA1A (0.44) | IDO1PDPK1ADRA1ASIGMAR1PRCP | |
| SCHEMBL10359810 | 0.71 | GID4 (0.48) | IDO1ADRA1ATAAR1 | |
| SCHEMBL2857779 | 0.71 | SLC6A2 (0.61) | HTR2ASIGMAR1MAOASLC6A2TAAR1 | |
| SCHEMBL2984209 | 0.71 | IDO1 (0.48) | IDO1HTR2APDPK1ADRA1ASIGMAR1 | |
| SCHEMBL8849605 | 0.71 | DDB1 (0.53) | IDO1HTR2APDPK1ADRA1ASIGMAR1 | |
| SCHEMBL11498923 | 0.69 | HTR2A (0.52) | IDO1HTR2APDPK1SIGMAR1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| CN-117715632-A | Compositions comprising an enzyme-cleavable prodrug and nafamostat and methods of use thereof | 恩赛斯生物科学股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4304576-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | Ensysce Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192197-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | Ensysce Biosciences Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | 3I, LP | 2022-09-15 | — | — | US | disclosed |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2020-08-13 | — | — | US | disclosed |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2016-08-18 | — | — | US | disclosed |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2560486-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120302590-A1 | METHODS AND COMPOSITIONS TO PREVENT ADDICTION | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012122412-A2 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2011133347-A1 | COMPOSITIONS COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | IDO1 396/4885HTR2A 375/4885PDPK1 3076/4885 |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | IDO1 396/4885HTR2A 375/4885PDPK1 3076/4885 |
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | DNPEP, PEPD, CEL | IDO1 2774/4885HTR2A 3854/4885PDPK1 2067/4885 |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | CYP2C19, CYP3A5, CYP3A4 | IDO1 602/4885HTR2A 823/4885PDPK1 1153/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | IDO1 1795/4885HTR2A 2491/4885PDPK1 3983/4885 |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | IDO1 396/4885HTR2A 375/4885PDPK1 3076/4885 |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | IDO1 396/4885HTR2A 375/4885PDPK1 3076/4885 |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | IDO1 396/4885HTR2A 375/4885PDPK1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.